CFA
INFI

Cahill Financial Advisors’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Cahill Financial Advisors’s Portfolio INFI Stock Details INFI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-115
Closed – – 839
2021
Q3 		$0 Buy
+115
New +$354 ﹤0.01% 868

Other funds holding INFI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
GC
Gratus Capital Atlanta, Georgia $2.5B AUM 32.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cahill Financial Advisors's INFI Position: Q4 2021 in Review

Cahill Financial Advisors sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2021, closing a stake of 115 shares.

Cahill Financial Advisors first reported a position in INFI in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 97 funds tracked by Wall St. Rank hold INFI as of Q4 2021.

  • Cahill Financial Advisors reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Cahill Financial Advisors sold 115 Infinity Pharmaceuticals, Inc. shares in Q4 2021.
  • Cahill Financial Advisors first reported a position in Infinity Pharmaceuticals, Inc. in Q3 2021 and held it in 1 quarter.
  • Cahill Financial Advisors's Infinity Pharmaceuticals, Inc. position peaked at $0 in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2021.

Based on Cahill Financial Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.